消化性潰瘍藥物市場規模、佔有率、成長分析，按藥物類型、潰瘍類型、最終用戶、地區 - 產業預測，2025-2032

2023年消化性潰瘍藥物市場規模將為47.6億美元，預測期內（2025-2032年）複合年成長率為3.50%，從2024年的49.3億美元成長到2032年的64.9億美元。

在多種促進因素​​的推動下，全球消化性潰瘍治療市場呈現上升趨勢。消化性潰瘍病影響著全球數百萬人，這種胃腸道疾病的盛行率不斷上升、人口老化以及吸煙和飲酒等不健康生活方式的迅速增加正在推動這一市場。醫療技術的進步和創新配方的推出進一步推動了市場的成長。然而，挑戰也存在，例如學名藥的可用性和替代治療方法的興起。然而，人們對早期診斷和有效治療重要性的認知不斷提高，預計將確保持續成長並推動市場在面對這些挑戰時向前發展。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

按藥物類型分類的消化性潰瘍治療藥物市場規模

• 市場概況
• 質子幫浦抑制劑
• H2拮抗劑
• 抗生素
• 其他

消化性潰瘍治療藥物市場規模：依潰瘍類型

• 市場概況
• 胃潰瘍
• 十二指腸潰瘍
• 食道潰瘍

消化性潰瘍治療藥物市場規模：依最終用戶分類

• 市場概況
• 醫院
• 零售藥房
• 網路藥房

消化性潰瘍治療藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• AstraZeneca plc.（United Kingdom）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc.（United Kingdom）
• Sanofi SA（France）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Bristol-Myers Squibb Company（United States）
• Mylan NV（Netherlands）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Ltd.（India）
• Lupin Ltd.（India）
• Zydus Cadila（India）

結論和建議

Peptic Ulcer Drugs Market size was valued at USD 4.76 Billion in 2023 and is poised to grow from USD 4.93 Billion in 2024 to USD 6.49 Billion by 2032, growing at a CAGR of 3.50% during the forecast period (2025-2032).

The global peptic ulcer drugs market is on an upward trajectory, fueled by various driving factors. With millions affected by peptic ulcer disease globally, the market is bolstered by the increasing prevalence of this gastrointestinal disorder, an expanding aging population, and a surge in unhealthy lifestyle choices like smoking and alcohol use. Technological advancements in medicine and the introduction of innovative drug formulations further enhance market growth. However, challenges exist, including the availability of generic drugs and the rise of alternative treatment options. Nonetheless, heightened awareness around the significance of early diagnosis and effective treatment is anticipated to propel the market forward, ensuring continued growth in the face of these challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segmental Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market is significantly driven by the rising prevalence of peptic ulcers across the globe. This common gastrointestinal condition impacts millions, creating a heightened demand for effective treatment alternatives. Contributing factors such as unhealthy lifestyles, increased stress levels, and the regular use of non-steroidal anti-inflammatory drugs (NSAIDs) are fueling the surge in peptic ulcer cases. As a result, there is a continued push for innovative and effective medications, fostering overall growth in the market. This increasing incidence emphasizes the urgent need for solutions, making the peptic ulcer drugs market an area of considerable focus and expansion.

Restraints in the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market faces restraint due to the presence of various alternative treatment options. Beyond conventional pharmaceutical interventions, patients often have access to non-pharmacological methods, such as lifestyle alterations, dietary adjustments, and natural remedies, which are perceived as effective alternatives for managing peptic ulcers. This preference for non-drug approaches can significantly diminish the demand for traditional medications. Additionally, concerns regarding the potential side effects and long-term risks associated with the use of peptic ulcer drugs may further deter patients and healthcare providers, thereby affecting overall market dynamics and growth potential.

Market Trends of the Peptic Ulcer Drugs Market

A prominent market trend in the global peptic ulcer drugs sector is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is fueled by the efficacy and safety of PPIs, which outperform other medication classes in reducing stomach acid production and providing lasting relief from ulcer symptoms. Enhanced drug formulations have further increased the bioavailability and compliance of PPIs in patients, making them more appealing. Such factors are contributing to a robust demand for these medications, positioning PPIs as a cornerstone in peptic ulcer therapies and fostering growth within the overall market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2025-2032)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations